Finance

Lists
MGX:NASDAQ
Metagenomi Therapeutics Inc
1,00 $
+0,68%
(+0,0068) 1D
1,00 $
0,00% (0,00)
After hours
Closed: 9 қаз., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGX...
Open
0,99 $
High
1,04 $
Low
0,99 $
Mkt. cap
37,90 млн
Avg. vol.
156,74 м.
Volume
147,18 м.
52-wk high
3,95 $
52-wk low
0,96 $
EPS
-2,49 $
Shares outstanding
37,78 млн
No. of employees
113
Open
0,99 $
High
1,04 $
Low
0,99 $
Mkt. cap
37,90 млн
Avg. vol.
156,74 м.
Volume
147,18 м.
52-wk high
3,95 $
52-wk low
0,96 $
EPS
-2,49 $
Shares outstanding
37,78 млн
No. of employees
113
News stories
From web sources and news partners
About Metagenomi Therapeutics Inc
CEO-
Employees113
Founded2016
HeadquartersEmeryville, Калифорния, Америка Құрама Штаттары
Sector-
Websitemetagenomi.co
Analyst ratings
Based on 4 analysts giving stock ratings to MGX in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MGX in the last 3 months.
Highest
Current 1,00 $
7,00 $ (+600,00%)
Average
6,00 $ (+500,00%)
Lowest
5,00 $ (+400,00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/11/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
7,00 $
+600%
08/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
5,00 $
+400%
08/10/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
5,00 $
+400%
07/07/2026
Last report
2026 ж. 10 там.
Fiscal period
Q2 2026
-0,73 $ / -0,52 $
-40,38%miss
Revenue / Est. (USD)
-257,00 м. / 2,93 млн
-108,76%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
8,66 млн
3,91 млн
1,25 млн
-257,00 м.
Cost of goods sold
25,28 млн
21,50 млн
19,30 млн
22,51 млн
Cost of revenue
25,28 млн
21,50 млн
19,30 млн
22,51 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,22 млн
6,78 млн
6,54 млн
6,00 млн
Operating expense
6,22 млн
6,78 млн
6,54 млн
6,00 млн
Total operating expenses
31,50 млн
28,28 млн
25,84 млн
28,52 млн
Operating income
-22,84 млн
-24,37 млн
-24,59 млн
-28,77 млн
Other non operating income
-2,00 мың
-11,00 мың
-1,00 мың
35,00 мың
EBT including unusual items
-20,63 млн
-22,49 млн
-23,05 млн
-27,48 млн
EBT excluding unusual items
-20,63 млн
-22,49 млн
-23,05 млн
-27,48 млн
Income tax expense
-234,00 м.
34,00 мың
10,00 мың
-
Effective tax rate
1,13%
-0,15%
-0,04%
-
Other operating expenses
-
-
-
-
Net income
-20,39 млн
-22,53 млн
-23,06 млн
-27,48 млн
Net profit margin
-235,51%
-576,02%
-1 847,68%
10 693,39%
Earnings per share
-0,55
-0,60
-0,61
-0,73
Interest and investment income
2,21 млн
1,88 млн
1,54 млн
1,26 млн
Interest expense
-
-
-
-
Net interest expenses
2,21 млн
1,88 млн
1,54 млн
1,26 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-21,52 млн
-23,07 млн
-23,31 млн
-27,51 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google қолданбалары